RGS6 in mesolimbic circuits as a therapeutic target for alcohol use disorders

中脑边缘回路中的 RGS6 作为酒精使用障碍的治疗靶点

基本信息

  • 批准号:
    10404071
  • 负责人:
  • 金额:
    $ 40.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary / Abstract Our broad goal is to provide novel mechanistic insight into the pathogenesis of alcohol use disorders (AUDs) by ascertaining how Regulator of G protein signaling 6 (RGS6) functions in the mesolimbic circuit as a critical modulator of alcohol (EtOH) seeking and reward behaviors. EtOH is the most commonly abused drug worldwide and, despite decades of research, the neurobiological mechanisms underlying EtOH seeking behavior and dependence are not fully understood. As a result, there are few effective therapeutics to reduce alcohol cravings or withdrawal symptomology, and abstinence remains the only way to prevent AUDs. This proposal is based upon our discovery that RGS6 promotes mouse EtOH seeking and reward behaviors and on a subsequent GWAS identifying RGS6 as a gene linked to human AUDs. Based on our previous work, we hypothesized that RGS6 promotes EtOH seeking behavior by negatively regulating neuronal Gαi/o-coupled receptors (GPCRs) implicated in alcoholism. Indeed, we found that RGS6-/- mice consume less EtOH when given free access and are less susceptible to EtOH reward, dependence and withdrawal. Antagonism of D2Rs or GABABRs and inhibition of dopamine transporter (DAT) activity, which is upregulated by Gαi/o-coupled GPCRs, partially and completely restored the reduced EtOH consumption in RGS6-/- mice, respectively. Our findings suggest that by inhibiting GPCR-Gαi-DAT upregulation in VTA DA neurons, RGS6 promotes EtOH-induced dopamine (DA) neurotransmission and behavioral responses. RGS6 control of this pathway would represent a previously unknown mechanism modulating the intensity and duration of Gαi signaling in VTA neurons to titre DA levels responsible for acute and chronic behavioral effects of EtOH. Here we propose to test the central hypothesis that RGS6 regulation of G protein signaling in VTA DA neurons plays a critical role in promoting dopaminergic neurotransmission responsible for EtOH seeking and reward behaviors. Aim 1 will determine the role of mesolimbic RGS6 on EtOH seeking and reward behaviors using mice with selective deletion of RGS6 in VTA DA neurons as well as rescue studies with RGS6 or its G protein-defective mutant. Aim 2 will determine the role of RGS6 in VTA DA neurotransmission and on EtOH consumption in mice using optogenetics. We will employ state of the art cell type-specific optogenetics, neuronal ensemble recordings and Ca2+ imaging in the NAc, as well as a novel EtOH-triggered optogenetic approach to determine how RGS6 modulates mesolimbic DA neurotransmission and EtOH consumption in real time in freely moving mice. These studies are significant as they will illuminate an entirely novel pathway in the mesolimbic circuit, a major dopaminergic pathway in the brain implicated in EtOH behavioral reward and addiction. We will address a critical barrier to progress in the understanding and treatment of AUDs as RGS6 has been identified as a human AUD-linked gene and we seek to increase our basic knowledge of its role in the mesolimbic circuit.
项目摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RORY A. FISHER其他文献

RORY A. FISHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RORY A. FISHER', 18)}}的其他基金

Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    8826575
  • 财政年份:
    2012
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    9034552
  • 财政年份:
    2012
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    8295899
  • 财政年份:
    2012
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    8458103
  • 财政年份:
    2012
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    7920567
  • 财政年份:
    2009
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    7674466
  • 财政年份:
    2007
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    7501461
  • 财政年份:
    2007
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    7385204
  • 财政年份:
    2007
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    7920779
  • 财政年份:
    2007
  • 资助金额:
    $ 40.12万
  • 项目类别:
Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
RGS6 作为新型生长抑制剂的分子分析和作用
  • 批准号:
    7678459
  • 财政年份:
    2007
  • 资助金额:
    $ 40.12万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了